Titan Pharmaceuticals, Inc. (TTNP)
NCM · Common · CUSIP 888314606
Last Price•••.••
Current Yield•.••%
Yield to Call•.••%
Yield to Worst•.••%
Free registration unlocks the quote, yield calculations, price chart and full fundamentals for TTNP and every other security on QuantumOnline.
🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type
Common Stock
CUSIP
888314606 (prev. 888314507 )
Market Cap
Micro Cap · $40 Million
Previous Symbol
TTP (changed 12/24/2008)
Business: Titan Pharmaceuticals, Inc. is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate is Probuphine, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.
Notes: November 30, 2020, following receipt of stockholder approval, the Company amended its certificate of incorporation to effect a 1-for-30 reverse split of its common stock. The shares began trading on a post-split basis on December 1, 2020 and have closed above the $1.00 minimum bid price since such date. Immediately after the reverse split becomes effective, there will be approximately 6.6 million shares of common stock issued and outstanding. The common shares will trade under a new CUSIP number, 888314606, effective December 1, 2020, and continue to trade under the symbol "TTNP." All stock options and warrants of the Company outstanding immediately prior to the reverse stock split have been proportionally adjusted.

Company Contact

CHR
Marc Rubin
CFO
Sunil Bhonsle
Headquarters
400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
Phone
650-244-4990
Fax
650-244-4956
Investor Relations
Stephen Kilmer · 650-989-2215 · skilmer@titanpharm.com
General Email
info@titanpharm.com
SEC EDGAR Filings
View filings »